Hepatitis Market Research Reports
The notion “hepatitis” means inflammation of the liver or its cells, often caused by some virus and accompanied in its initial phase to by symptoms similar to flu: fever, loss of appetite, muscle/joint aches, etc. According to the virus type hepatitis is divided into several types: hepatitis A, В C, D and E. Hepatitis can disappear on its own, but in some cases it can lead to serious liver dysfunctions and severe complications such as fibrosis, liver failure or cancer, cryoglobulinemia, an a lot more.
The world hepatitis drugs market has experienced stable growth over the recent years, driven by the constant increase of demand from developed countries, introduction of new products and technological advancement in the medical industry. It is set to continue growing at a CARG of above 12% through 2015. Gilead Sciences, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb and Hoffmann-La Roche are amid the key hepatitis market players.
The collection of the research reports found in this catalogue provides an extensive insight into the hepatitis market at different geographical scales. Relevant information on the market size, share, segmentation as well as major factors influencing the market is presented in the researches. The reports offer detailed assessment of the competitive landscape and profile top companies. In addition, discussions of future market prospects for the are at hand in the research reports.
EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022 Summary Hepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV). HCV ... associated with injection drug use, which accounts for up to 60% of all reported HCV cases (ECDC, 2010). China and Brazil’s prevalent HCV ...
Mar, 2013 58 pages... key players involved in the therapeutic development for Hepatitis. Hepatitis - Pipeline Review, Half Year is built using data and information sourced ... on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons to ...
Mar, 2013 527 pages... the industry analysis specialist, has released its new report, “Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential ... data from 2006 to 2011, forecast for eight years to 2019. Pipeline analysis data providing a split across the different phases, mechanisms ...
Mar, 2012 103 pages... key players involved in the therapeutic development for Hepatitis C. Hepatitis C - Pipeline Review, Half Year is built using data and information sourced ... on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons ...
Feb, 2013 257 pages... bar and the expectations of pts, physicians and investors. Freedom from IFN, treating all genotypes and betting on vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of $230m followed by GILD buying VRUS for $11b, ...
Feb, 2013 31 pages... introduction more effective and tolerable pipeline agents. Therapy Trends Consensus Outlook: Hepatitis C analyses the global HCV market players and ... results to in-depth discussions with leading key opinion leaders (KOLs). Consensus forecasts also act as an excellent benchmark against which other projections ...
Dec, 2012The report contains 320 pages, 93 tables and presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and ... presents sales and market share estimates for major suppliers of Hepatitis tests. Also, the report examines the market applications of DNA ...
Nov, 2012 320 pages... market. Key Benefits Hepatitis C: the race for the first interferon-free regimen examines the most prominent insights gained from ... markets in other countries. In order to critically select Key Opinion Leaders (KOLs) a number of parameters were considered including their clinical experience, scientific ...
Nov, 2012 246 pages... and explores the competitive landscape, including major players in the hepatitis C therapeutics market. Finally, the report also includes analysis of the Mergers and ... launch of oral DAA molecules, the first of which should be in the market in 2015. Further, combinations of DAA drugs will improve the overall ...
Oct, 2012 113 pages... data driven report contains over 190 links to online copies of actual hepatitis deals and contract documents as submitted to the Securities Exchange Commission ... , providing easy access to each contract document on demand. Benefits Hepatitis Partnering 2007-2013 provides the reader with the following key ...
Jan, 2013 100 pages... key players involved in the therapeutic development for Hepatitis D. Hepatitis D - Pipeline Review, Half Year is built using data and information sourced ... on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons ...
Dec, 2012 47 pages... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Keywords Hepatitis A Clinical Trials, Trial Designs, Subjects Recruited, Unaccomplished Trials of Hepatitis A , Pfizer, AstraZeneca, Novartis, ...
Jun, 2012 71 pages
